Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 590

1.

Improving Cancer Diagnosis and Care: Patient Access to Oncologic Imaging Expertise.

Nass SJ, Cogle CR, Brink JA, Langlotz CP, Balogh EP, Muellner A, Siegal D, Schilsky RL, Hricak H.

J Clin Oncol. 2019 May 3:JCO1801970. doi: 10.1200/JCO.18.01970. [Epub ahead of print] No abstract available.

PMID:
31050908
2.

Extracapsular extension on MRI indicates a more aggressive cell cycle progression genotype of prostate cancer.

Wibmer AG, Robertson NL, Hricak H, Zheng J, Capanu M, Stone S, Ehdaie B, Brawer MK, Vargas HA.

Abdom Radiol (NY). 2019 Apr 27. doi: 10.1007/s00261-019-02023-1. [Epub ahead of print]

PMID:
31030245
3.

Prospective Study of the Radiolabeled GRPR Antagonist BAY86-7548 for Positron Emission Tomography/Computed Tomography Imaging of Newly Diagnosed Prostate Cancer.

Touijer KA, Michaud L, Alvarez HAV, Gopalan A, Kossatz S, Gonen M, Beattie B, Sandler I, Lyaschenko S, Eastham JA, Scardino PT, Hricak H, Weber WA.

Eur Urol Oncol. 2019 Mar;2(2):166-173. doi: 10.1016/j.euo.2018.08.011. Epub 2018 Sep 22.

PMID:
31017093
4.

The Influence of Background Signal Intensity Changes on Cancer Detection in Prostate MRI.

Hötker AM, Dappa E, Mazaheri Y, Ehdaie B, Zheng J, Capanu M, Hricak H, Akin O.

AJR Am J Roentgenol. 2019 Apr;212(4):823-829. doi: 10.2214/AJR.18.20295. Epub 2019 Feb 4.

PMID:
30714830
5.

Recommendations for the Initial Cancer Staging MRI Report.

Panicek DM, Hricak H.

J Magn Reson Imaging. 2019 May;49(5):1209-1211. doi: 10.1002/jmri.26528. Epub 2019 Jan 4. No abstract available.

PMID:
30609211
6.

News From the Academy.

Hricak H, Seltzer SE.

Acad Radiol. 2019 Apr;26(4):578. doi: 10.1016/j.acra.2018.11.012. Epub 2018 Dec 6. No abstract available.

PMID:
30528752
7.

Association between CT-texture-derived tumor heterogeneity, outcomes, and BRCA mutation status in patients with high-grade serous ovarian cancer.

Meier A, Veeraraghavan H, Nougaret S, Lakhman Y, Sosa R, Soslow RA, Sutton EJ, Hricak H, Sala E, Vargas HA.

Abdom Radiol (NY). 2018 Nov 24. doi: 10.1007/s00261-018-1840-5. [Epub ahead of print]

PMID:
30474722
8.

Accelerating anticancer drug development - opportunities and trade-offs.

Nass SJ, Rothenberg ML, Pentz R, Hricak H, Abernethy A, Anderson K, Gee AW, Harvey RD, Piantadosi S, Bertagnolli MM, Schrag D, Schilsky RL.

Nat Rev Clin Oncol. 2018 Dec;15(12):777-786. doi: 10.1038/s41571-018-0102-3. Review.

PMID:
30275514
9.

Global Challenges for Cancer Imaging.

Schlemmer HP, Bittencourt LK, D'Anastasi M, Domingues R, Khong PL, Lockhat Z, Muellner A, Reiser MF, Schilsky RL, Hricak H.

J Glob Oncol. 2018 Sep;4:1-10. doi: 10.1200/JGO.17.00036. Epub 2017 Sep 8.

10.

Characterization of prostate cancer with MR spectroscopic imaging and diffusion-weighted imaging at 3 Tesla.

Mazaheri Y, Shukla-Dave A, Goldman DA, Moskowitz CS, Takeda T, Reuter VE, Akin O, Hricak H.

Magn Reson Imaging. 2019 Jan;55:93-102. doi: 10.1016/j.mri.2018.08.025. Epub 2018 Aug 31.

PMID:
30176373
11.

Temporal changes in MRI appearance of the prostate after focal ablation.

Hötker AM, Meier A, Mazaheri Y, Zheng J, Capanu M, Chaim J, Sosa R, Coleman J, Hricak H, Akin O.

Abdom Radiol (NY). 2019 Jan;44(1):272-278. doi: 10.1007/s00261-018-1715-9.

PMID:
30069583
12.

Trends in oncologic hybrid imaging.

Wibmer AG, Hricak H, Ulaner GA, Weber W.

Eur J Hybrid Imaging. 2018;2(1):1. doi: 10.1186/s41824-017-0019-6. Epub 2018 Jan 19. Review.

13.

Effect of intravascular contrast agent on diffusion and perfusion fraction coefficients in the peripheral zone and prostate cancer.

Mazaheri Y, Hötker AM, Shukla-Dave A, Akin O, Hricak H.

Magn Reson Imaging. 2018 Sep;51:120-127. doi: 10.1016/j.mri.2018.04.007. Epub 2018 Apr 17.

PMID:
29678542
14.

CT Features of Ovarian Tumors: Defining Key Differences Between Serous Borderline Tumors and Low-Grade Serous Carcinomas.

Nougaret S, Lakhman Y, Molinari N, Feier D, Scelzo C, Vargas HA, Sosa RE, Hricak H, Soslow RA, Grisham RN, Sala E.

AJR Am J Roentgenol. 2018 Apr;210(4):918-926. doi: 10.2214/AJR.17.18254. Epub 2018 Feb 28.

PMID:
29489407
15.

Dynamic contrast-enhanced magnetic resonance imaging of prostate cancer: A review of current methods and applications.

Mazaheri Y, Akin O, Hricak H.

World J Radiol. 2017 Dec 28;9(12):416-425. doi: 10.4329/wjr.v9.i12.416. Review.

16.

2016 New Horizons Lecture: Beyond Imaging-Radiology of Tomorrow.

Hricak H.

Radiology. 2018 Mar;286(3):764-775. doi: 10.1148/radiol.2017171503. Epub 2018 Jan 18.

PMID:
29346031
17.

Prostate cancer in 2017: Advances in imaging.

Wibmer AG, Vargas HA, Hricak H.

Nat Rev Urol. 2018 Feb;15(2):81-82. doi: 10.1038/nrurol.2017.210. Epub 2017 Dec 12. No abstract available.

PMID:
29231198
18.

Background, current role, and potential applications of radiogenomics.

Pinker K, Shitano F, Sala E, Do RK, Young RJ, Wibmer AG, Hricak H, Sutton EJ, Morris EA.

J Magn Reson Imaging. 2018 Mar;47(3):604-620. doi: 10.1002/jmri.25870. Epub 2017 Nov 2. Review.

19.

Model selection for high b-value diffusion-weighted MRI of the prostate.

Mazaheri Y, Hötker AM, Shukla-Dave A, Akin O, Hricak H.

Magn Reson Imaging. 2018 Feb;46:21-27. doi: 10.1016/j.mri.2017.10.003. Epub 2017 Oct 12.

PMID:
29031583
20.

High-Grade Serous Ovarian Cancer: Associations between BRCA Mutation Status, CT Imaging Phenotypes, and Clinical Outcomes.

Nougaret S, Lakhman Y, Gönen M, Goldman DA, Miccò M, D'Anastasi M, Johnson SA, Juluru K, Arnold AG, Sosa RE, Soslow RA, Vargas HA, Hricak H, Kauff ND, Sala E.

Radiology. 2017 Nov;285(2):472-481. doi: 10.1148/radiol.2017161697. Epub 2017 Jun 16.

Supplemental Content

Loading ...
Support Center